Pharmacological Interventions of Selenium in Duchene Muscular Dystrophy: The Role of Reactive Oxygen Species in Mediating Lipid Peroxide Formation by Westermarck, Tuomas et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 18
Pharmacological Interventions of Selenium in Duchene
Muscular Dystrophy: The Role of Reactive Oxygen
Species in Mediating Lipid Peroxide Formation
Tuomas Westermarck, Shirly Ekvall and
Kaski Markus
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57370
1. Introduction
The muscular dystrophies are a group of muscle diseases which have three features in
common: they are hereditary; they are progressive; and each causes a characteristic, selective
pattern of weakness. Duchenne muscular dystrophy (DMD) is the most common inherited
muscular disease, affecting one in 3,500 male births. DMD is characterized by rapid, progres‐
sive muscle wasting that typically kills patients in their twenties. Complete muscle dystrophin
deficiency is a common mechanism for DMD.
Duchenne muscular dystrophy (DMD) is a severe X-linked recessive, progressive muscle-
wasting disease affecting one in 3500 boys (Emery AEH, 1993). Patients are usually confined
to a wheelchair before the age of 12 and die in their late teens or early twenties usually of
respiratory failure. A milder form of the disease, Becker muscular dystrophy (BMD), has a
later onset and a much longer survival.
The most widely studied dystrophies are those due to mutations in the dystrophin gene. In
humans, dystrophin deficiency leads to the severe disease, Duchenne muscular dystrophy,
whereas reductions or truncations of dystrophin lead to a milder disease, Becker muscular
dystrophy. Numerous animal models of dystrophin deficiency are actively studied, but none
more so than the mdx mouse. Despite over a decade of study of dystrophin and its associated
proteins, some of which themselves cause muscular dystrophies when deficient or defective,
the mechanisms by which the primary biochemical defects lead to muscle cell death remain
to be determined.
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Both disorders are caused by mutations in the DMS gene that encodes a 427-kDa cytoskeletal
protein called dystrophin. The vast majority of DMD mutations result in the complete absence
of dystrophin, whereas the presence of low levels of a truncated protein is seen in BMD
patients. The defected gene causes a shortage or absence of the structural protein dystrophin,
which is near the sites of Ca 2+ release from sarcoplasmic reticulum and uptake of intracellular
Ca 2+. The genetic alteration produces an abnormality in the membrane of muscular fibers that
consists of a disturbance in the calcium transport (Ca++), inside the muscular fibers, which is
the base mechanism of cellular degeneration, necrosis, and apoptosis (Simonian and Coyle
1996). A nucleotide degeneration and decreased muscle AP and ADP content has been
reported. Of the total body selenium reserves consists of muscle selenium supply. Selenium
is gradually wasted out by the kidneys during the proceeding of the dystrophy of the legs
(Westermarck et al 1982). Open follow-up trials with antioxidants are indicating positive
clinical response (Gebre-Medhin et al 1985; Timberg 1989; Westermarck et al 1997).
2. Description and clinical features of Duchenne
Typically, DMD patients are clinically normal at birth, although serum levels of muscle isoform
of creatine kinase are elevated. The onset of pseudohypertrophy of the calf muscles, proximal
limb muscle weakness suggests DMD. Weakness of the arms occurs later along with progres‐
sive kyphoscoliosis (Dubowitz. Major Probl Clin Pediatr 1978).
Most patients die in their early twenties as a result of respiratory complications due to
intercostal muscle weakness and respiratory infection. Death can also be the result of cardiac
dysfunction with cardiomyopathy. BMD and DMD patients also present with mild cognitive
impairment, indicating that brain function is also abnormal in these disorders (Blak and
Martin-Rendon, 2002).
Fetal DMD is histologically normal except for occasional eosinophilic hypercontracted fibers
(Bertorini et al. 1984). Necrotic or degenerating muscle fibers are seen in all postnatal DMD
muscle biopsies even before muscle weakness is clinically seen. The necrotic fibers are
phagocytized, and muscle biopsies from DMD patients reveal the presence of inflammatory
cells at perimysial and endomysiel sites (Arahata and Engel 1984). The regenerative capacity
of the muscle is lost and muscle fibers are gradually replaced by adipose and fibrous connective
tissue, giving rise to the clinical appearance of pseudohypertrophy followed by atrophy
(Emery 1993), resulting in muscle wasting and ultimately muscle weakness (Blake et al 2002).
Most patients die in their early twenties as a result of respiratory complications due to
intercostal muscle weakness and respiratory infection. Death can also be the result of cardiac
dysfunction with cardiomyopathy. BMD and DMD patients also present with mild cognitive
impairment, indicating that brain function is also abnormal in these disorders (Blake and
Kroger 2000).
DMD muscle shows signs of oxidative damage (Murphy and Kehrer 1989). Muscle diseases
in which oxidative damage may play a primary role show features in common with DMD
(Mendell Et al 1971). Moreover, muscle cells from mdx mice have an increased susceptibility
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to oxidative stress (Rando et al 1998). The lack of neuronal-type nitric oxide synthase (nNOS)
seen in DMD causes disregulation of vascular tone, and ischemia (Crosbie 2001, Blake et al
2002). This henomenon may increase the generation of free radicals. Open follow-up trials with
antioxidants are indicating positive clinical response (Gebre-Medhin et al 1985; Timber 1989;
Westermarck et al 1997).
A low blood selenium level has previously been observed in healthy inhabitants of Finland
(WESTERMARCK, 1977). In this study even lower blood selenium values were observed in
patients with acrodermatitis enteropathica, dystrophia musculorum progressiva (Duchenne),
infantile and juvenile type of neuronal ceroid lipofuscinosis (NCL), severe mental retardation
caused by various factors, and myocardial infarction. The selenium content of the brain, heart,
kidney and liver in patients of different ages was also determined. The highest selenium level
was found in the kidney. The mean liver selenium concentrations in stillborn, premature and
full-term neonates were 1.11 +/- 0.23 (8), 1.21 +/- 0.17 (12) and 0.93 +/- 0.16 microgram/g dry
weight (12) respectively (the number of subjects in parentheses). The selenium values are
considerably higher than those in infants of from one to nine months of age and adults, whose
liver selenium values were 0.58 +/- 0.21 (8) and 0.67 +/- 0.08 microgram/g dry weight (8)
respectively. The vitamin E levels of serum in patients with NCL, as well as in subjects with
severe mental retardation (controls), were low compared with values in healthy normal
subjects. Sodium selenite supplementation in patients with NCL produced at least a transitory
improvement without causing any toxic effects during one year of administration. In Duch‐
enne muscular dystrophy we found that 75Se-selenite was not absorbed in the lower extremities
in the equal level compared to healthy ones.
3. Oxidative stress
Oxidative stress is often defined as an imbalance between the generation of reactive oxygen
species and the removal of such species by enzymatic and nonenzymatic cellular defense
systems (Figure 1). This imbalance could arise from overproduction of reactive species, as
occurs under certain pathologic conditions and in association with inflammation, or from an
impairment of the defense mechanisms, as occurs in certain genetic loss-of-function disorders
and deficiency states. Implicit in this definition is the notion that such an imbalance is sufficient
to lead to the oxidation of various cellular constituents and to cause cellular dysfunction and
injury. As such, oxidative stress may also be viewed as a condition in which the production of
oxidative products exceeds their removal by cellular repair mechanisms. Such conditions may
lead to acute cellular dysfunction or cell death, and chronic tissue degeneration, if such changes
accumulate.
During normal cellular metabolism, the primary generation of reactive oxygen species comes
from the leakage of superoxide anions from the electron transport chain. A series of linked
enzymatic reactions are responsible for the detoxification of superoxide. Superoxide is
converted to hydrogen peroxide by the action of superoxide dismutase (SOD). Most animal
cells contain two forms of SOD, a cytoplasmic Cu,Zn-SOD and a mitochondrial Mn-SOD. In
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addition, there is an extracellular form of the enzyme. Hydrogen peroxide is subsequently
metabolized to oxygen and water by the selenium-containing enzyme glutathione peroxidase,
which uses glutathione (GSH) as a cofactor in the reaction. Glutathione peroxidase converts
most of the hydrogen peroxide in the cytoplasm. At sites of relatively high concentrations of
hydrogen peroxide, such as peroxisomes, catalase is an important antioxidant enzyme that
also converts hydrogen peroxide to water. Hydrogen peroxide can react with metal ions in the
cell to produce the highly reactive hydroxyl radical, and superoxide can react with nitric oxide
(NO•) to produce peroxynitrite. Hydroxyl radical and peroxynitrite are among the most
reactive species present in biological systems and are capable of oxidizing nucleic acids,
proteins, lipids, and carbohydrate moieties in the cell.
Figure 1. The role of free radical in inflammation
4. Oxidative stress cause dystrophic changes
One of the first observations that led to the oxidative stress hypothesis was the finding that
vitamin E deficiency in animals leads to muscle degeneration with pathologic characteristics
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very similar to those of the muscular dystrophies. The similarities are most striking in avian
species in which vitamin E deficiency myopathies closely mimic the hereditary dystrophies
both anatomically and biochemically. In humans, vitamin E deficiency is associated with
myopathic changes, and in these disorders, there is selective involvement of type IIB fibers as
in the inherited muscular dystrophies. Vitamin E refers to a group of compounds of which
[alpha]-tocopherol is the most potent and most prevalent in animal tissues as the major lipid-
soluble antioxidant in the cell. Deficiencies of vitamin E are associated with increases in lipid
peroxidation and decreases in polyunsaturated fatty acids in muscle and compensatory
increases in muscle antioxidant enzymes and GSH levels. Although it is clear that inherited
muscular dystrophies are not due to primary deficiencies in vitamin E, as was once proposed,
the cumulative data strongly support the proposition that the mechanism of muscle injury is
the same in both conditions.
5. Can antioxidant treatment ameliorate muscular dystrophy
In addition to evidence of oxidative damage preceding pathologic changes, amelioration of
the pathology of a muscular dystrophy by antioxidant treatment would be strong support for
the hypothesis that oxidative stress is a primary pathogenetic process. Various antioxidant
treatments have been tried in humans and animals with muscular dystrophy. However, the
benefit from any individual antioxidant treatment would depend on the actual nature of the
oxidative stress that is occurring in the muscle tissue. For example, supplementation of vitamin
E–deficient animals with the most prevalent cellular soluble antioxidant, ascorbic acid (vitamin
C), does not significantly improve the myopathy. Different susceptibilities to oxidative stress
are not identical. Even if oxidative stress is indeed the primary pathophysiologic process
leading to muscle cell death in the dystrophies, effective treatment will need to be targeted to
the specific deficit in antioxidant defense in the dystrophic muscle and thus will depend on a
detailed understanding of the nature of that susceptibility.
Antioxidant treatments in animals with hereditary muscular dystrophies have provided
modest benefits. Penicillamine, a sulfhydryl compound with antioxidant properties, and
vitamin E slowed the degenerative process in avian dystrophy. Research showed that iron
deprivation resulted in a significant reduction of necrosis in the mdx mouse, presumably by
a decrease in the production of hydroxyl radical. Dietary supplementation rich in antioxidants
significantly reduced an index of muscle weakness in mdx mice.
Clinical trials of antioxidant therapy in humans with Duchenne muscular dystrophy have
included treatments with tocopherols, ascorbate, penicillamine, and SOD. No clear benefit has
been found from any of these treatments. However, these trials have been very limited in
duration and size. Furthermore, in no human study has antioxidant treatment begun early in
the course of the disease. In fact, all of these studies involved boys with advanced disease
(average age, >=10 yr). Based on the notion that oxidative injury is critical to the pathogenesis
of muscle cell death and that antioxidant treatment might be effective to prevent such death,
trials in humans would need to be initiated early in the course of the disease, and efficacy
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would need to be assessed primarily as the slowing, not a reversal, of muscle loss. The
difficulties and pitfalls of clinical trials for new treatments of muscular dystrophies are well
known. Thus, based on both statistical power and theoretical benefit, none of these human
trials would even be predicted to demonstrate any benefit, and the negative results do not in
any way refute the oxidative stress hypothesis.
6. Selenium in the brain and brain diseases
Oxidative stress and generation of reactive oxygen species (ROS) are strongly implicated in a
number of neuronal and neuromuscular disorders, including stroke and cerebrovascular
disease, Alzheimer's disease, Parkinson's disease, familial amyotrophic lateral sclerosis, and
Duchenne muscular dystrophy (Dexter et al. 1989a,b; Smith et al. 1991; Ragusa et al. 1997;
Cornett et al. 1998b; Facchinetti et al. 1998; Sagara et al. 1998; Tan et al. 1998). Selenium is known
to provide protection from ROS-induced cell damage, and the proposed mechanisms mainly
invoke the functions of glutathione peroxidases (GPxs) and selenoprotein P (SelP).
Considerable evidence exists linking heavy metals to neurodegenerative diseases (Thompson
et al. 1988; Deibel et al. 1996; Cuajungco and Lees 1997; Schionning et al. 1997; Cornett et al.
1998b; Ely 2001). Heavy metals trigger the conversion of hydrogen peroxide to hydroxyl radical
through Fenton reaction. Selenium has long been known to function as an antidote to toxicity
of heavy metals. Co-administration of selenium was reported to play a role in reducing the
toxic effects of mercury as early as the 1970s (Koelman et al. 1973; Kosta et al. 1975). Among
the selenoproteins, SelP has been reported in several studies to possess metal-binding function
(see below). The GPxs might also detoxify heavy metals through their well-known function of
eliminating peroxides (Figure 2).
Figure 2. Complementary actions of selenium (GSH-Px) in free radical formation and lipid peroxidation (from Para‐
ntainen et al., 1987)
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7. Treatment of brain diseases with selenium
Two children with severe neurodevelopmental retardation and elevated liver function tests
developed intractable seizures during the first years of life. They were found systemically
selenium deficient. Oral substitution with selenium supplements in both children (3–5 µg/kg
body weight) resulted in reduction of seizures, improvement of the electroencephalogram
(EEG) recordings, and return of normal liver function after 2 weeks (Ramaekers et al. 1994). It
is unknown if selenium deficiency is a direct factor for the neurodevelopmental retardation or
it affected the brain via abnormal liver function.
Methamphetamine (MA) exposure of animals results in enhanced formation of superoxide
radical (O2-) and nitric oxide (NO), which interact to produce peroxynitrite (OONO-). Perox‐
ynitrite is a potent oxidant, leading to dopaminergic damage (Imam and Ali 2000). Thus,
multiple dose administration of MA to mice results in long-lasting toxic effects in the nigros‐
triatal dopaminergic system, which is a relevant model of PD. In selenium-replete mice, this
dopaminergic toxicity was significantly attenuated, compared with selenium-deficient mice
(Kim et al. 1999; Kim et al. 2000). Pre-treatment of animals with selenium and melatonin can
completely protect against the depletion of striatal dopamine induced by MA exposure (Imam
et al. 2001). The reason for the protective effects of selenium against MA was reported to be
the efficient scavenging of peroxynitrite by selenoproteins (Sies and Arteel 2000).
6-hydroxydopamine (6-OHDA) is a neurotoxin specific for catecholamine neurons in both the
central and peripheral nervous system. PD induced by this compound in rats was prevented
by selenium in a dose-dependent manner, through up-regulating the antioxidant status and
lowering the dopamine loss. This study revealed that selenium may be helpful in slowing
down the progression of neurodegeneration in Parkinsonism (Zafar et al. 2003).
8. Hypotesis and intervention
It is possible to improve the life quality of Duchenne patients by biological active substances
(antioxidants), and psychotherapeutic intervention. Therapy of DMD has been an elusive goal.
Studies with isolated myocytes have shown that lipid peroxidation with an enhanced free
radical production can be activated by increasing Ca concentration. No wonder that several
kinds of antioxidants have been proposed as a treatment since increased levels of thiobarbituric
acid (TBA) reactive material has been found in the muscles and blood of patients with DMD.
Vitamin E has been observed to decrease the amount of TBA reactive material in dystrophic
muscle. Previously we have reported that the biological half-life of selenium -75 (75Se) in DMD
patients is significantly shorter than in healthy controls (Westermarck et al 1982). On the basis
of these facts we started to treat some DMD patients with selenium and other antioxidants.
Selenium is activating a well-known antioxidative enzyme glutathione peroxidase (GSH-Px,
iodothyronine desiodinase, selenoprotein P, thioredoxin reductase and the selenoprotein W,
that all contain selenocystein. Beside iodothyronine desiodinase that facilitates the activation
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of thyroid hormones; all other selenoproteins have a role in the metabolisation and detoxifi‐
cation of reactive oxygen species and in the maintenance of the antioxidant defense of cells.
For example, in 1981 the antioxidant treatment of two siblings with DMD, aged six and ten
years, was started. At that time the older brother was wheel-chair bound and was not able to
walk since eight years of age, the younger one was still able to walk almost normally. The
condition of the older brother, who practically had not got carnitine or coenzyme Q10 supple‐
mentation, was gradually deteriorated, and he deceased at 17 years of age. However, at the
age of 15 years the younger brother was still able to walk without any assistance. Six months
later he became wheel-chair bound. The younger brother was one of the most talented
graduated students in his high-school. The mean IQ of DMD patients is without treatment
15-20 points lower than that of normal populations. Anyway for some years he was able to
study at the University of Joensuu. Now he is 31 years old and still able to swim some meters,
and to produce computer art. Actually he had his first art-show in 2003 in Helsinki. Moreover,
only during the nights it is necessary to give him non-invasive breathing assistance.
The present daily megadoses of nutrients supplements (vitamin E 1200mg; sodium selenite
8mg; riboflavin 3mg; pyridoxine 75mg; carnitine 600mg; and coenzyme Q10 180mg) have been
well tolerated and no side effects have observed in our open controlled trial (Westermarck et
al 1997). The long-term pilot study speaks in favor for a larger study. Dr. Anders Erikson from
Sweden (personal communication) has made the same observations with two Swedish siblings
suffering from DMD, as we have also made with two 13- and 14-year old cousins 2with DMD.
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